These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 16434506)

  • 1. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation.
    Campistol JM; Eris J; Oberbauer R; Friend P; Hutchison B; Morales JM; Claesson K; Stallone G; Russ G; Rostaing L; Kreis H; Burke JT; Brault Y; Scarola JA; Neylan JF
    J Am Soc Nephrol; 2006 Feb; 17(2):581-9. PubMed ID: 16434506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study.
    Oberbauer R; Kreis H; Johnson RW; Mota A; Claesson K; Ruiz JC; Wilczek H; Jamieson N; Henriques AC; Paczek L; Chapman J; Burke JT;
    Transplantation; 2003 Jul; 76(2):364-70. PubMed ID: 12883194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Similar lipid profile but improved long-term outcomes with sirolimus after cyclosporine withdrawal compared to sirolimus with continuous cyclosporine.
    Morales JM; Hartmann A; Walker R; Arns W; Senatorski G; Grinyó JM; Shoker A; Wilczek H; Jamieson NV; Lelong M; Brault Y; Burke JT; Scarola JA;
    Transplant Proc; 2009; 41(6):2339-44. PubMed ID: 19715914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies.
    Mathew T; Kreis H; Friend P
    Clin Transplant; 2004 Aug; 18(4):446-9. PubMed ID: 15233824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation.
    Oberbauer R; Segoloni G; Campistol JM; Kreis H; Mota A; Lawen J; Russ G; Grinyó JM; Stallone G; Hartmann A; Pinto JR; Chapman J; Burke JT; Brault Y; Neylan JF;
    Transpl Int; 2005 Jan; 18(1):22-8. PubMed ID: 15612979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-related quality-of-life outcomes of sirolimus-treated kidney transplant patients after elimination of cyclosporine A: results of a 2-year randomized clinical trial.
    Oberbauer R; Hutchison B; Eris J; Arias M; Claesson K; Mota A; Kreis H; Kleinman L; Wang F; Chen J; Revicki DA;
    Transplantation; 2003 Apr; 75(8):1277-85. PubMed ID: 12717216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
    Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors influencing glomerular filtration rate in renal transplantation after cyclosporine withdrawal using sirolimus-based therapy: a multivariate analysis of results at five years.
    Legendre C; Brault Y; Morales JM; Oberbauer R; Altieri P; Riad H; Mahony J; Messina M; Pussell B; Martínez JG; Lelong M; Burke JT; Neylan JF;
    Clin Transplant; 2007; 21(3):330-6. PubMed ID: 17488381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sirolimus-based therapy with or without cyclosporine: long-term follow-up in renal transplant patients.
    Morales JM; Campistol JM; Kreis H; Mourad G; Eris J; Schena FP; Grinyo JM; Nanni G; Andres A; Castaing N; Brault Y; Burke JT
    Transplant Proc; 2005 Mar; 37(2):693-6. PubMed ID: 15848504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Better actual 10-year renal transplant outcomes of 80% reduced cyclosporine exposure with sirolimus base therapy compared with full cyclosporine exposure without or with concomittant sirolimus treatment.
    Pliszczynski J; Kahan BD
    Transplant Proc; 2011 Dec; 43(10):3657-68. PubMed ID: 22172822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-year health-related quality-of-life outcomes for sirolimus-treated kidney transplant patients after elimination of cyclosporine.
    Russ G; Jamieson N; Oberbauer R; Arias M; Murgia MG; Blancho G; Sato R; Stoeckl M; Revicki DA
    Transpl Int; 2007 Oct; 20(10):875-83. PubMed ID: 17854445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of posttransplant diabetes mellitus in kidney transplant recipients immunosuppressed with sirolimus in combination with cyclosporine.
    Romagnoli J; Citterio F; Nanni G; Favi E; Tondolo V; Spagnoletti G; Salerno MP; Castagneto M
    Transplant Proc; 2006 May; 38(4):1034-6. PubMed ID: 16757255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of anemia in sirolimus-treated renal transplant recipients: the importance of preserving renal function.
    Friend P; Russ G; Oberbauer R; Murgia MG; Tufveson G; Chapman J; Blancho G; Mota A; Grandaliano G; Campistol JM; Brault Y; Burke JT;
    Transpl Int; 2007 Sep; 20(9):754-60. PubMed ID: 17565578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical insights for cancer outcomes in renal transplant patients.
    Alberú J
    Transplant Proc; 2010 Nov; 42(9 Suppl):S36-40. PubMed ID: 21095450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients.
    Felipe CR; Park SI; Pinheiro-Machado PG; Garcia R; Casarini DE; Moreira S; Tedesco-Silva H; Medina-Pestana JO
    Fundam Clin Pharmacol; 2009 Oct; 23(5):625-31. PubMed ID: 19656203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Superior outcomes in renal transplantation after early cyclosporine withdrawal and sirolimus maintenance therapy, regardless of baseline renal function.
    Russ G; Segoloni G; Oberbauer R; Legendre C; Mota A; Eris J; Grinyó JM; Friend P; Lawen J; Hartmann A; Schena FP; Lelong M; Burke JT; Neylan JF;
    Transplantation; 2005 Nov; 80(9):1204-11. PubMed ID: 16314787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure.
    Johnson RW; Kreis H; Oberbauer R; Brattström C; Claesson K; Eris J
    Transplantation; 2001 Sep; 72(5):777-86. PubMed ID: 11571437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. De novo cancer in cyclosporine-treated and non-cyclosporine-treated adult primary renal allograft recipients.
    Gruber SA; Gillingham K; Sothern RB; Stephanian E; Matas AJ; Dunn DL
    Clin Transplant; 1994 Aug; 8(4):388-95. PubMed ID: 7949545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of sirolimus to cyclosporine in long-term kidney transplant recipients to withdraw steroid.
    Citterio F; Sparacino V; Altieri P; Rigotti P; Calabrese S; Poli M; Vinti V; Segoloni GP
    Transplant Proc; 2005 Mar; 37(2):827-9. PubMed ID: 15848545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.